Device Trial Radar · NCT07178080
Comparing a New 3D Technology Used to Measure Thyroid Nodule Volume to Standard Ultrasound
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
75
Planned (sponsor's estimate)
Start
Sep 8, 2025
Primary completion
Sep 8, 2027
Study completion Sep 8, 2027
Sponsor
- Lead sponsor
- Sarasota Memorial Health Care SystemAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
After thyroid ablation procedure, the volume of the thyroid nodule (s) needs to be measured to see how well the procedure worked. Currently, these volumes are measured using traditional 2D ultrasound imaging. However, this approach comes with limitations because of the information 2D images cannot gather and because of differences in these measurements between different doctors. A new ultrasound technology called PIUR 3D imaging offers a novel alternative approach. The system uses advanced technology to create 3D images and can generate automated volume estimates. The PIUR imaging system, PIUR tUS Infinity, has been cleared by the Food and Drug Administration (FDA) to aid in treatment decisions when used alongside traditional 2D ultrasound imaging. The purpose of this study is to test how effective and consistent the PIUR imaging technology is compared to standard 2D ultrasound in measuring thyroid nodule volume.
Conditions
- Thyroid Nodules
- Thyroid Nodule
Interventions
PIUR tUS Infinity UltrasoundDevice
PIUR imaging technology, cleared by the U.S. Food and Drug Administration under 510(k) (K240036), is designed to provide advanced volumetric imaging capabilities to improve accuracy in assessing nodule size and volume reduction.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thyroid nodule volumetric measurementsTime frame: Will occur at baseline, 2 weeks, 1 month, 3 months, 6 months, and 1 year
- Comparison of variability between measurementsTime frame: Will occur at baseline, 2 weeks, 1 month, 3 months, 6 months, and 1 year
- Post-ablation thyroid volume reduction rate comparisonTime frame: 2 weeks, 1-, 3-, 6-, and 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sarasota Memorial Health Care System
Sarasota, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.